Targeting the canonical Wnt/β-catenin pathway in hematological malignancies

Cancer Science

Volumn 106, Issue 6, 2015, Pages 665-671

  Ashihara, Eishi ^a   Takada, Tetsuya ^a   Maekawa, Taira ^b  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Canonical Wnt pathway; Hematological malignancies; High throughput screening; Small molecule inhibitors; Catenin

Indexed keywords

7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; ALPHA CATENIN; BCR ABL PROTEIN; BETA CATENIN; CD34 ANTIGEN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; MYC PROTEIN; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; PROTEIN; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; WNT1 PROTEIN; WNT2B PROTEIN; WNT3 PROTEIN; WNT5A PROTEIN;

ACTIN FILAMENT; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL RENEWAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; CPG ISLAND; DNA METHYLATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; LEUKEMOGENESIS; LYMPHOMA; MESENCHYMAL STROMA CELL; MULTIPLE MYELOMA; NEURAL STEM CELL; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SOMATIC MUTATION; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; BONE MARROW; CANCER STEM CELL; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HEMATOLOGIC NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BETA CATENIN; BONE MARROW; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

EID: 84930414869     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12655     Document Type: Review

References (71)

1. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003; 94: 225-9.
2. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004; 5: 691-701.
3. Malhotra S, Kincade PW. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell 2009; 4: 27-36.
4. Lento W, Congdon K, Voermans C, Kritzik M, Reya T. Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol 2013; 5: 1-10.
5. Ko KH, Holmes T, Palladinetti P et al. GSK-3beta inhibition promotes engraftment of ex vivo-expanded hematopoietic stem cells and modulates gene expression. Stem Cells 2011; 29: 108-18.
6. Baba Y, Garrett KP, Kincade PW. Constitutively active beta-catenin confers multilineage differentiation potential on lymphoid and myeloid progenitors. Immunity 2005; 23: 599-609.
7. Zhao C, Blum J, Chen A et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528-41.
8. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 2006; 7: 1048-56.
9. Scheller M, Huelsken J, Rosenbauer F et al. Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. Nat Immunol 2006; 7: 1037-47.
10. Chung EJ, Hwang SG, Nguyen P et al. Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood 2002; 100: 982-90.
11. Serinsoz E, Neusch M, Busche G, Wasielewski R, Kreipe H, Bock O. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Br J Haematol 2004; 126: 313-9.
12. Ysebaert L, Chicanne G, Demur C et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia 2006; 20: 1211-6.
13. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 2005; 24: 2410-20.
14. Abu-Duhier FM, Goodeve AC, Wilson GA et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190-5.
15. Meshinchi S, Woods WG, Stirewalt DL et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89-94.
16. Tickenbrock L, Schwable J, Wiedehage M et al. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 2005; 105: 3699-706.
17. Muller-Tidow C, Steffen B, Cauvet T et al. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24: 2890-904.
18. Okamura RM, Sigvardsson M, Galceran J, Verbeek S, Clevers H, Grosschedl R. Redundant regulation of T cell differentiation and TCRalpha gene expression by the transcription factors LEF-1 and TCF-1. Immunity 1998; 8: 11-20.
19. Reya T, O'Riordan M, Okamura R et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000; 13: 15-24.
20. Kuhnl A, Gokbuget N, Kaiser M et al. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood 2011; 118: 6362-7.
21. Gutierrez A Jr, Tschumper RC, Wu X et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 2010; 116: 2975-83.
22. Gelebart P, Anand M, Armanious H et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 2008; 112: 5171-9.
23. Khan NI, Bradstock KF, Bendall LJ. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 2007; 138: 338-48.
24. Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-47.
25. Lu D, Zhao Y, Tawatao R et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 3118-23.
26. Sukhdeo K, Mani M, Zhang Y et al. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 2007; 104: 7516-21.
27. Ashihara E, Kawata E, Nakagawa Y et al. beta-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 2009; 15: 2731-8.
28. Qiang YW, Endo Y, Rubin JS, Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene 2003; 22: 1536-45.
29. Yao H, Ashihara E, Strovel JW et al. AV-65, a novel Wnt/beta-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer J 2011; 1: e43.
30. Liang W, Yang C, Qian Y, Fu Q. Effects of short-hairpin RNA-inhibited beta-catenin expression on the growth of human multiple myeloma cells in vitro and in vivo. Biochem Biophys Res Commun 2012; 422: 681-6.
31. Schilham MW, Wilson A, Moerer P, Benaissa-Trouw BJ, Cumano A, Clevers HC. Critical involvement of Tcf-1 in expansion of thymocytes. J Immunol 1998; 161: 3984-91.
32. Staal FJ, Meeldijk J, Moerer P et al. Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription. Eur J Immunol 2001; 31: 285-93.
33. Guo Z, Dose M, Kovalovsky D et al. Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood 2007; 109: 5463-72.
34. Van Camp JK, Beckers S, Zegers D, Van Hul W. Wnt signaling and the control of human stem cell fate. Stem Cell Rev 2014; 10: 207-29.
35. de Lau W, Barker N, Low TY et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 2011; 476: 293-7.
36. Qu Q, Sun G, Li W et al. Orphan nuclear receptor TLX activates Wnt/beta-catenin signalling to stimulate neural stem cell proliferation and self-renewal. Nat Cell Biol 2010; 12: 31-40 sup pp 1-9.
37. Wang Y, Krivtsov AV, Sinha AU et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650-3.
38. Jabbour E, Cortes J, Ravandi F, O'Brien S, Kantarjian H. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol 2013; 50: 271-83.
39. Kimura S. Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone. Recent Pat Anti-Cancer Drug Discovery 2006; 1: 347-55.
40. Michor F, Hughes TP, Iwasa Y et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-70.
41. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Investig 2011; 121: 396-409.
42. Jamieson CH. Chronic myeloid leukemia stem cells. Hematology Am Soc Hematol Educ Program 2008; 1: 436-42.
43. Lenz HJ, Kahn M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci 2014; 105: 1087-92.
44. Hou HA, Kuo YY, Liu CY et al. Distinct association between aberrant methylation of Wnt inhibitors and genetic alterations in acute myeloid leukaemia. Br J Cancer 2011; 105: 1927-33.
45. Valencia A, Roman-Gomez J, Cervera J et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia 2009; 23: 1658-66.
46. Roman-Gomez J, Cordeu L, Agirre X et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007; 109: 3462-9.
47. Chim CS, Pang R, Fung TK, Choi CL, Liang R. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 2007; 21: 2527-36.
48. Wang H, Fan R, Wang XQ et al. Methylation of Wnt antagonist genes: a useful prognostic marker for myelodysplastic syndrome. Ann Hematol 2013; 92: 199-209.
49. Fleming HE, Janzen V, Lo Celso C et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2008; 2: 274-83.
50. Ichii M, Frank MB, Iozzo RV, Kincade PW. The canonical Wnt pathway shapes niches supportive of hematopoietic stem/progenitor cells. Blood 2012; 119: 1683-92.
51. Dufourcq P, Descamps B, Tojais NF et al. Secreted frizzled-related protein-1 enhances mesenchymal stem cell function in angiogenesis and contributes to neovessel maturation. Stem Cells 2008; 26: 2991-3001.
52. Zhang B, Li M, McDonald T et al. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 2013; 121: 1824-38.
53. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 2007; 104: 5431-6.
54. Cipolleschi MG, Dello Sbarba P, Olivotto M. The role of hypoxia in the maintenance of hematopoietic stem cells. Blood 1993; 82: 2031-7.
55. Takeuchi M, Kimura S, Kuroda J et al. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Differ 2010; 17: 1211-20.
56. Nagao R, Ashihara E, Kimura S et al. Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65-a novel Wnt/beta-catenin signaling inhibitor. Cancer Lett 2011; 312: 91-100.
57. Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer 2014; 14: 248-62.
58. Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des 2013; 19: 634-64.
59. Lepourcelet M, Chen YN, France DS et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004; 5: 91-102.
60. Minke KS, Staib P, Puetter A et al. Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells. Eur J Haematol 2009; 82: 165-75.
61. Gandhirajan RK, Staib PA, Minke K et al. Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Neoplasia 2010; 12: 326-35.
62. Huang SM, Mishina YM, Liu S et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009; 461: 614-20.
63. Yang Y, Mallampati S, Sun B et al. Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target. Cancer Lett 2013; 333: 9-17.
64. Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA 2004; 101: 12682-7.
65. Gang EJ, Hsieh YT, Pham J et al. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene 2013; 33: 2169-2178.
66. Kida A, Kahn M. Hypoxia selects for a quiescent, CML stem/leukemia initiating-like population dependent on CBP/catenin transcription. Curr Mol Pharmacol 2013; 6: 204-10.
67. El-Khoueiry AB, Ning Y, Yang D et al. A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors. J Clin Oncol 2013; 31: 2501 (abstr.)
68. Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005; 24: 3619-31.
69. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci USA 2002; 99: 14789-94.
70. Bol D, Ebner R. Gene expression profiling in the discovery, optimization and development of novel drugs: one universal screening platform. Pharmacogenomics 2006; 7: 227-35.
71. Fiskus W, Sharma S, Saha S et al. Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia 2014; in press. doi: 10.1038/leu.2014.340.